The Prescription Opioid Addiction Treatment Study: What have we learned

Drug and Alcohol Dependence

Volumn 173, Issue , 2017, Pages S48-S54

  Weiss, Roger D ^a,b   Rao, Vinod ^b,c  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Addiction; Follow up; Opioid use disorder; Outcome; Prescription opioids; Treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; NARCOTIC ANALGESIC AGENT;

CHRONIC PAIN; FOLLOW UP; HELP SEEKING BEHAVIOR; HUMAN; OPIATE ADDICTION; PAIN SEVERITY; PATIENT COUNSELING; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DRUG MISUSE; HEROIN DEPENDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE, NALOXONE DRUG COMBINATION; COMBINED MODALITY THERAPY; COUNSELING; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE;

EID: 85030439184     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.12.001     Document Type: Review

References (58)

1. Anton, R.F., Oroszi, G., O'Malley, S., Couper, D., Swift, R., Pettinati, H., Goldman, D., An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65 (2008), 135–144.
2. Arfken, C.L., Johanson, C.E., di Menza, S., Schuster, C.R., Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J. Subst. Abuse Treat. 39 (2010), 96–104.
3. Barry, D.T., Beitel, M., Joshi, D., Schottenfeld, R.S., Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment. Am. J. Addict. 18 (2009), 117–121.
4. Bodkin, J.A., Zornberg, G.L., Lukas, S.E., Cole, J.O., Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 15 (1995), 49–57.
5. Carroll, K.M., Weiss, R.D., The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am. J. Psychiatry, 2017 (in press).
6. Center for Behavioral Health Statistics and Quality, 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health, NSDUH Series H-50, HHS Publication No. SMA 15-4927.
7. Crane, E.H., The CBHSQ Report: Emergency Department Visits Involving Narcotic Pain Relievers, Substance Abuse and Mental Health Services Administration., 2015, Center for Behavioral Health Statistics and Quality, Rockville, MD.
8. Dreifuss, J.A., Griffin, M.L., Frost, K., Fitzmaurice, G.M., Potter, J.S., Fiellin, D.A., Selzer, J., Hatch-Maillette, M., Sonne, S.C., Weiss, R.D., Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend. 131 (2013), 112–118.
9. Dunn, K.E., Saulsgiver, K.A., Miller, M.E., Nuzzo, P.A., Sigmon, S.C., Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Drug Alcohol Depend. 151 (2015), 47–55.
10. Fiellin, D.A., Pantalon, M.V., Schottenfeld, R.S., Gordon, L., O'Connor, P.G., Standard Medication Management for Bup/Nx Treatment of Opioid Analgesic Dependence for Use in NIDA CTN-0030 Unpublished Manual. 1999, Yale University.
11. Fiellin, D.A., Pantalon, M.V., Chawarski, M.C., Moore, B.A., Sullivan, L.E., O'Connor, P.G., Schottenfeld, R.S., Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 355 (2006), 365–374.
12. Fiellin, D.A., Barry, D.T., Sullivan, L.E., Cutter, C.J., Moore, B.A., O'Connor, P.G., Schottenfeld, R.S., A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am. J. Med. 126 (2013), 74.e11–74.e17.
13. Fiellin, D.A., Schottenfeld, R.S., Cutter, C.J., Moore, B.A., Barry, D.T., O'Connor, P.G., Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern. Med. 174 (2014), 1947–1954.
14. Fudala, P.J., Bridge, T.P., Herbert, S., Williford, W.O., Chiang, C.N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R.J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., Tusel, D., Buprenorphine/Naloxone Collaborative Study, Group, Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 349 (2003), 949–958.
15. Griffin, M.L., Dodd, D.R., Potter, J.S., Rice, L.S., Dickinson, W., Sparenborg, S., Weiss, R.D., Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. Am. J. Drug Alcohol Abuse 40 (2014), 157–162.
16. Gruber, V.A., Delucchi, K.L., Kielstein, A., Batki, S.L., A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 94 (2008), 199–206.
17. Johnson, B.A., Ait-Daoud, N., Seneviratne, C., Roache, J.D., Javors, M.A., Wang, X.Q., Liu, L., Penberthy, J.K., DiClemente, C.C., Li, M.D., Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 168 (2011), 265–275.
18. Jones, C.M., Logan, J., Gladden, R.M., Bohm, M.K., Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. Morb. Mortal. Wkly. Rep. (MMWR) 64 (2015), 719–725.
19. Jones, C.M., Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 132 (2013), 95–100.
20. Keller, S., Bann, C.M., Dodd, S.L., Schein, J., Mendoza, T.R., Cleeland, C.S., Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin. J. Pain 20 (2004), 309–318.
21. Kranzler, H.R., Covault, J., Feinn, R., Armeli, S., Tennen, H., Arias, A.J., Gelernter, J., Pond, T., Oncken, C., Kampman, K.M., Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am. J. Psychiatry 171 (2014), 445–452.
22. Krupitsky, E., Nunes, E.V., Ling, W., Illeperuma, A., Gastfriend, D.R., Silverman, B.L., Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377 (2011), 1506–1513.
23. LaBelle, C.T., Han, S.C., Bergeron, A., Samet, J.H., Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers. J. Subst. Abuse Treat. 60 (2016), 6–13.
24. Lee, J.D., Friedmann, P.D., Kinlock, T.W., Nunes, E.V., Boney, T.Y., Hoskinson, R.A. Jr., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M.N., Gordon, M., Fishman, M., Chen, D.T., Bonnie, R.J., Cornish, J.W., Murphy, S.M., O'Brien, C.P., Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N. Engl. J. Med. 374 (2016), 1232–1242.
25. Ling, W., Charuvastra, C., Collins, J.F., Batki, S., Brown, L.S. Jr., Kintaudi, P., Wesson, D.R., McNicholas, L., Tusel, D.J., Malkerneker, U., Renner, J.A. Jr., Santos, E., Casadonte, P., Fye, C., Stine, S., Wang, R.I., Segal, D., Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93 (1998), 475–486.
26. Ling, W., Hillhouse, M., Ang, A., Jenkins, J., Fahey, J., Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 108 (2013), 1788–1798.
27. Mattick, R.P., Breen, C., Kimber, J., Davoli, M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev., 2, 2014, CD002207.
28. McDermott, K.A., Griffin, M.L., Connery, H.S., Hilario, E.Y., Fiellin, D.A., Fitzmaurice, G.M., Weiss, R.D., Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J. Clin. Psychiatry 76 (2015), 189–194.
29. McLellan, A.T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., Argeriou, M., The fifth edition of the Addiction Severity Index. J. Subst. Abuse Treat. 9 (1992), 199–213.
30. McLellan, A.T., Arndt, I.O., Metzger, D.S., Woody, G.E., O'Brien, C.P., The effects of psychosocial services in substance abuse treatment. JAMA 269 (1993), 1953–1959.
31. Moore, B.A., Fiellin, D.A., Barry, D.T., Sullivan, L.E., Chawarski, M.C., O'Connor, P.G., Schottenfeld, R.S., Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 22 (2007), 527–530.
32. Moore, B.A., Fiellin, D.A., Cutter, C.J., Buono, F.D., Barry, D.T., Fiellin, L.E., O'Connor, P.G., Schottenfeld, R.S., Cognitive Behavioral Therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. J. Subst. Abuse Treat. 71 (2016), 54–57.
33. Nielsen, S., Hillhouse, M., Thomas, C., Hasson, A., Ling, W., A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J. Addict. Med. 7 (2013), 33–38.
34. Nyhuis, P.W., Gastpar, M., Scherbaum, N., Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J. Clin. Psychopharmacol. 28 (2008), 593–595.
35. Pantalon, M.V., Fiellin, D.A., Schottenfeld, R.S., Gordon, L., O'Connor, P.G., Manual for Enhanced Medical Management of Opioid Dependence with Buprenorphine. Unpublished Manuscript. 1999, Yale University.
36. Potter, J.S., Prather, K., Weiss, R.D., Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities. Am. J. Addict. 17 (2008), 121–125.
37. Potter, J.S., Marino, E.N., Hillhouse, M.P., Nielsen, S., Wiest, K., Canamar, C.P., Martin, J.A., Ang, A., Baker, R., Saxon, A.J., Ling, W., Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J. Stud. Alcohol Drugs 74 (2013), 605–613.
38. Potter, J.S., Dreifuss, J.A., Marino, E.N., Provost, S.E., Dodd, D.R., Rice, L.S., Fitzmaurice, G.M., Griffin, M.L., Weiss, R.D., The multi-site prescription opioid addiction treatment study: 18-month outcomes. J. Subst. Abuse Treat. 48 (2015), 62–69.
39. Rosenblum, A., Joseph, H., Fong, C., Kipnis, S., Cleland, C., Portenoy, R.K., Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 289 (2003), 2370–2378.
40. Rosenblum, A., Parrino, M., Schnoll, S.H., Fong, C., Maxwell, C., Cleland, C.M., Magura, S., Haddox, J.D., Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 90 (2007), 64–71.
41. Rudd, R.A., Aleshire, N., Zibbell, J.E., Gladden, R.M., Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. Morb. Mortal. Wkly. Rep. 64 (2016), 1378–1382.
42. Schwartz, R.P., Kelly, S.M., O'Grady, K.E., Gandhi, D., Jaffe, J.H., Interim methadone treatment compared to standard methadone treatment: 4-month findings. J. Subst. Abuse Treat. 41 (2011), 21–29.
43. Senay, E.C., Jaffe, J.H., diMenza, S., Renault, P.F., A 48-week study of methadone, methadyl acetate and minimal services. Fisher, S., Freeman, A., (eds.) Opiate Dependence: Origins and Treatment, 1973, Halstead Press, New York, NY, 185–201.
44. Sigmon, S.C., Dunn, K.E., Saulsgiver, K., Patrick, M.E., Badger, G.J., Heil, S.H., Brooklyn, J.R., Higgins, S.T., A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70 (2013), 1347–1354.
45. Sigmon, S.C., Characterizing the emerging population of prescription opioid abusers. Am. J. Addict. 15 (2006), 208–212.
46. Sobell, L.C., Sobell, M.B., Timeline followback: a technique for assessing self-reported alcohol consumption. Litten, R.Z., Allen, J.P., (eds.) Measuring Alcohol Consumption: Psychosocial and Biochemical Methods, 1992, Humana Press, Totowa, NJ, 41–72.
47. Stein, M.D., Cioe, P., Friedmann, P.D., Buprenorphine retention in primary care. J. Gen. Intern. Med. 20 (2005), 1038–1041.
48. Substance Abuse, Mental Health Services Administration, Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. 2014, Substance Abuse and Mental Health Services Administration, Rockville, MD.
49. Tetrault, J.M., Moore, B.A., Barry, D.T., O'Connor, P.G., Schottenfeld, R., Fiellin, D.A., Fiellin, L.E., Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J. Subst. Abuse Treat. 43 (2012), 433–439.
50. Thomas, C.P., Fullerton, C.A., Kim, M., Montejano, L., Lyman, D.R., Dougherty, R.H., Daniels, A.S., Ghose, S.S., Delphin-Rittmon, M.E., Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr. Serv. 65 (2014), 158–170.
51. Tompkins, D.A., Bigelow, G.E., Harrison, J.A., Johnson, R.E., Fudala, P.J., Strain, E.C., Concurrent validation of the clinical opiate withdrawal scale (COWS) and single-item indices against the clinical institute narcotic assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 105 (2009), 154–159.
52. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
53. Weiss, R.D., Potter, J.S., Copersino, M.L., Prather, K., Jacobs, P., Provost, S., Chim, D., Selzer, J., Ling, W., Conducting clinical research with prescription opioid dependence: defining the population. Am. J. Addict. 19 (2010), 141–146.
54. Weiss, R.D., Potter, J.S., Fiellin, D.A., Byrne, M., Connery, H.S., Dickinson, W., Gardin, J., Griffin, M.L., Gourevitch, M.N., Haller, D.L., Hasson, A.L., Huang, Z., Jacobs, P., Kosinski, A.S., Lindblad, R., McCance-Katz, E.F., Provost, S.E., Selzer, J., Somoza, E.C., Sonne, S.C., Ling, W., Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 68 (2011), 1238–1246.
55. Weiss, R.D., Griffin, M.L., Potter, J.S., Dodd, D.R., Dreifuss, J.A., Connery, H.S., Carroll, K.M., Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?. Drug Alcohol Depend. 140 (2014), 118–122.
56. Weiss, R.D., Potter, J.S., Griffin, M.L., McHugh, R.K., Haller, D., Jacobs, P., Gardin, J., Fischer, 2nd, Rosen, D., Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J. Subst. Abuse Treat. 47 (2014), 140–145.
57. Weiss, R.D., Potter, J.S., Griffin, M.L., Provost, S.E., Fitzmaurice, G.M., McDermott, K.A., Srisarajivakul, E.N., Dodd, D.R., Dreifuss, J.A., McHugh, R.K., Carroll, K.M., Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 150 (2015), 112–119.
58. World Health Organization, January 1997. Composite International Diagnostic Interview (CIDI): Core Version 2.1, Geneva, Switzerland.